Table 2 NCE formulations
From: Differential diffusion of pharmaceutical innovations in a mixed market middle - income economy
ATC Level 1 Category | Number of NCEs (% of total medicines) | Expenditure (% of total values) | Utilization (% of total DDDs) | ||||||
|---|---|---|---|---|---|---|---|---|---|
|  | Public n = 180 | Private n = 193 | Panel n = 171 | Public n = 180 | Private n = 193 | Panel n = 171 | Public n = 180 | Private n = 193 | Panel n = 171 |
A – Alimentary tract and metabolism | 13.9 | 14.0 | 12.9 | 16.8 | 34.9 | 27.3 | 67.5 | 49.5 | 52.1 |
B – Blood and blood forming organs | 11.7 | 11.9 | 11.7 | 17.8 | 12.1 | 14.5 | 2.8 | 4.0 | 4.0 |
C – Cardiovascular system | 11.7 | 10.4 | 11.7 | 4.5 | 21.1 | 15.5 | 7.4 | 25.5 | 20.9 |
D – Dermatalogicals | 1.1 | 1.0 | 1.2 | 0.3 | 0.8 | 0.6 | 0.2 | 0.8 | 0.6 |
G – Genito – urinary system and sex hormones | 7.2 | 9.3 | 7.6 | 6.4 | 11.1 | 9.1 | 12.6 | 12.9 | 13.9 |
J – Anti-infectives for systemic use | 5.0 | 3.6 | 4.1 | 2.0 | 1.9 | 2.0 | 0.7 | 0.4 | 0.5 |
L – Antineoplastic agents and immunomodulating agents | 17.8 | 18.7 | 18.7 | 10.0 | 8.8 | 9.4 | 0.3 | 1.0 | 0.8 |
M – Musculo – skeletal system | 2.2 | 2.1 | 2.3 | 0.4 | 1.5 | 1.2 | 0.4 | 1.4 | 1.1 |
N – Nervous system | 22.8 | 20.7 | 23.4 | 41.4 | 5.3 | 18.7 | 7.9 | 1.6 | 4.3 |
R – Respiratory system | 5.6 | 5.7 | 5.8 | 0.5 | 2.3 | 1.7 | 0.4 | 2.4 | 1.8 |
S – Sensory Organs | 0.6 | 1.6 | 0.6 | < 0.1 | 0.3 | < 0.1 | < 0.1 | 0.5 | < 0.1 |